AnaptysBio (ANAB) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of AnaptysBio (NASDAQ: ANAB) in the last few weeks:

• 11/14/2024 – AnaptysBio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
• 11/12/2024 – AnaptysBio had its price target lowered by analysts at JPMorgan Chase & Co. from $75.00 to $66.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – AnaptysBio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
• 11/6/2024 – AnaptysBio had its price target lowered by analysts at HC Wainwright from $55.00 to $52.00. They now have a “buy” rating on the stock.
• 10/31/2024 – AnaptysBio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
• 10/30/2024 – AnaptysBio had its price target raised by analysts at UBS Group AG from $23.00 to $33.00. They now have a “neutral” rating on the stock.
• 10/21/2024 – AnaptysBio had its price target raised by analysts at Guggenheim from $75.00 to $90.00. They now have a “buy” rating on the stock.
• 9/26/2024 – AnaptysBio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.

AnaptysBio Stock Performance

ANAB opened at $19.00 on Monday. The company has a market cap of $578.15 million, a PE ratio of -3.13 and a beta of -0.24. The stock has a 50-day moving average of $31.06 and a 200-day moving average of $29.91. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. On average, research analysts predict that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the transaction, the insider now directly owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. The trade was a 55.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,440 shares of company stock valued at $892,936. 33.70% of the stock is owned by corporate insiders.

Institutional Trading of AnaptysBio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of AnaptysBio by 3.0% during the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock worth $15,594,000 after buying an additional 13,336 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of AnaptysBio by 2.0% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after acquiring an additional 43,598 shares during the last quarter. Barclays PLC lifted its stake in shares of AnaptysBio by 117.4% in the 3rd quarter. Barclays PLC now owns 44,300 shares of the biotechnology company’s stock valued at $1,486,000 after purchasing an additional 23,926 shares during the period. XTX Topco Ltd lifted its stake in shares of AnaptysBio by 49.1% in the 3rd quarter. XTX Topco Ltd now owns 20,286 shares of the biotechnology company’s stock valued at $680,000 after purchasing an additional 6,683 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of AnaptysBio by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 65,939 shares of the biotechnology company’s stock worth $2,209,000 after purchasing an additional 3,048 shares during the last quarter.

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.